Clinical Trials Sep 27, 2026 · 1 min read · 60,336 views

Akeso details survival win for its PD-1xVEGF drug versus Keytruda

Elena Marsh

Editorial · Sep 27, 2026

Akeso/Summit's ivonescimab cut death risk 27% vs Merck's Keytruda in HARMONi-2 lung cancer trial; median survival 30.75 vs 22.57 months

← Previous

RevMed, BeOne make clinical trial, Asia deal; MoonLake reports Phase 3 win

Updated: Electra says $350M IPO will help it become a commercial biotech

Related Reading

Roche kidney drug's Phase 3 win sets up path to accelerated approval

Sep 28, 2026

RevMed, BeOne make clinical trial, Asia deal; MoonLake reports Phase 3 win

Sep 27, 2026

Celldex falls on safety concern, even as chronic hives drug succeeds in Phase 3 trials

Sep 26, 2026